Twin Capital Management upped its stake in Bristol-Myers Squibb by 11.2% in Q4, grabbing 92,094 shares valued over $5.2 ...

Bristol Myers Squibb (BMY) ended the recent trading session at $53.78, demonstrating a +1.34% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 9.52%.

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take ...

Bristol-Myers Squibb Co. got dismissal of a lawsuit alleging the company used reverse-payment agreements to delay the generic ...

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

A New York City federal court has dismissed a proposed class action lawsuit against Bristol Myers Squibb that accused the ...

Bristol-Myers Squibb Down Nearly 6%, on Pace for Largest Percent Decrease Since April 2024 — Data Talk Bristol-Myers Squibb Company (BMY) is currently at $49.98, down $3.09 or 5.82% ...

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent ...

Shares in major U.S. and European pharmaceutical companies fell sharply Wednesday, underperforming a broader market downturn, after U.S. President Donald Trump said the country would soon impose “a ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Bristol Myers Squibb (BMY) wins dismissal of a lawsuit filled by Blue Cross Blue Shield of Louisiana alleging antitrust trust ...